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Abstract
Research involving human subjects can impose risk on some ‘bystanders’– people who are not themselves research sub-
jects but whom the study may affect. We examine the consequences of research for a particular category of bystanders
– research subjects’ sex partners – in trials testing interventions to reduce (1) HIV transmission (HIV treatment-as-
prevention trials) and (2) HIV acquisition (HIV pre-exposure prophylaxis trials). Both types of trials provide useful test
cases for assessing whether bystanders to research deserve special consideration in ethics reviews, and potentially some
of the benefits and protections that research subjects receive. In HIV treatment-as-prevention trials, there are two
groups of people who are alike in many important respects but treated very differently by research ethics: research sub-
jects who contribute data on the primary endpoint of the trial (because some of them have sex with the people receiving
the treatment conditions of the trials) – and bystanders who are not enrolled in the trials but who could have contribu-
ted primary endpoint data in the same way as the first group. In pre-exposure trials, the sex partners of people partici-
pating in pre-exposure prophylaxis trials are bystanders, even though they are necessary for the success of the trial.
Research subjects’ autonomy is fiercely protected by trial enrolment processes. Bystanders, by contrast, often have no
choice but to be affected by the study, because of their relationship to a research subject. In HIV prevention trials, stand-
ing by can come with important risks, including the same ones on which the success of the research hinges. It is thus
important to consider the ethical obligations to protect bystanders, and the related procedural responsibilities.
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Prevention of HIV transmission: HIV
treatment-as-prevention trials
Several large, population-based treatment-as-
prevention trials have recently been carried out in sub-
Saharan Africa1–5 to test the hypothesis that high levels
of HIV treatment coverage can reduce HIV incidence
at the population level. In these trials, the people who
receive the treatment conditions are not the same as the
people in whom the endpoint is measured. The latter
are people who are HIV-negative at the inception of
the trial, live in the communities participating in the
trials, and have given their individual consent to parti-
cipating in the HIV incidence cohorts required for end-
point assessment.1,2,4,5 As research subjects, these
people are protected by the rules and processes of for-
mal ethics review and oversight. The reason why the
people enrolled in the HIV incidence cohort are needed
for the research is that some of them will have sex with
the people receiving the treatment conditions of the
trials. The comparison of HIV incidence among those
who have sex with the trial participants receiving the
intervention versus the control condition is a measure
of the effectiveness of treatment-as-prevention in pre-
venting the transmission.
Other people, however, will also have sex with the
people who are receiving the treatment conditions of
the trials. These people face many of the same risks as
those enrolled in the incidence cohorts of the trials –
such as increased risk of HIV acquisition because of
behavioural risk compensation, or increased risk of
acquiring a resistant strain of HIV because of resistance
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development. These people are bystanders, because they
face study-borne risks without being study subjects.
There are thus two groups of people who are alike
in many important respects but treated very differently
by research ethics regulations and by the resulting pro-
cesses. The first group is research subjects who contrib-
ute data on the primary endpoint of the trial, because
some of them have sex with the people receiving the
treatment conditions of the trials. The second group is
bystanders who are not enrolled in the trials but who
could have contributed primary endpoint data in the
same way as the first group, because some of them also
have sex with the people receiving the treatment condi-
tions. Indeed, in several of the treatment-as-prevention
trials, the people offered participation in the HIV inci-
dence cohorts for endpoint assessment are randomly
selected from the larger population of people who are
HIV-negative and live in the communities where the
trials take place.1,2 This random selection into trial par-
ticipation ensures that the two groups will indeed be
equal in all respects, with the exception of the prospec-
tive endpoint measurement.
The existence of the two groups raises questions for
research ethics. Ought these two groups be treated
equally within the trial operations? Should they have
similar consent rights? Should they receive the same
benefits and protections, such as, in one of the
treatment-as-prevention trials, ‘on-the-spot voluntary
counselling and testing using rapid HIV test kits’ and
referral ‘to a health centre for further management’ if
an HIV test is positive?2 Currently, only one group –
those who contribute endpoint data – receives those
benefits and protections. The other group – bystanders
– does not.
Prevention of HIV acquisition: HIV pre-
exposure prophylaxis trials
Administering antiretroviral drugs to people who do
not have HIV, but who are at high risk of contracting
the disease, is commonly referred to as HIV pre-
exposure prophylaxis. The hope is that pre-exposure
prophylaxis will prevent acquisition of HIV if someone
is exposed.6 Sex partners of people participating in pre-
exposure prophylaxis trials are bystanders as well, but
of a very different type. In these trials, sex partners are
necessary in order to ensure that some primary research
subjects are at risk of incident HIV infection, the end-
point of the trial. Indeed, in pre-exposure prophylaxis
trials, having a sex partner is often an inclusion criter-
ion.7,8 The sexual partners who ‘stand by’ are thus not
only intimately connected to the research subjects but
also a necessary requirement for the success of the
research. And these bystanders face potential risks
from the research subjects’ participation in the pre-
exposure prophylaxis trial. Such risks include the risk
of becoming infected with a resistant strain of HIV –
for example, if the trial subject adheres only partially to
the pre-exposure prophylaxis regimen,9 or increased
risk of acquiring another sexually transmitted disease –
if the trial subject ‘compensates’ for the perceived
reduced risk of HIV acquisition by increasing the fre-
quency of unprotected sex.10 Bystanders who are sexual
partners of people participating in pre-exposure pro-
phylaxis trials may also face a range of other risk, such
as stigma, dignitary harms, HIV status disclosure and
violence. Stigma and dignitary harms could come to
the ‘community’ of trial participants’ sexual partners, if
it became known that many of them are HIV-positive
and can thus transmit the virus. HIV infections
observed in a pre-exposure prophylaxis trial imply that
a participant’s sex partner is HIV-positive, which might
lead to status disclosure and violence. Some pre-
exposure prophylaxis trials are conceived as ‘couple
studies’, enrolling both partners in HIV-discordant
couples. Many others, however, enrol only the person
who receives pre-exposure prophylaxis, while her sex
partner remains an unenrolled bystander – unknown to
the trial management and without the benefits, consent
rights, and protections that research subjects typically
receive.11
Benefits and protections for bystanders?
Both treatment-as-prevention and pre-exposure pro-
phylaxis trials provide useful test cases for assessing
whether certain bystanders to research deserve special
consideration in ethics review, and potentially some of
the benefits and protections that research subjects
receive. For instance, research subjects’ autonomy is
fiercely protected by trial enrolment processes. By con-
trast, bystanders are rarely informed about the trial
and its nature. Often their relationship to the trial sub-
ject leaves them no choice except to be affected by the
study. In HIV prevention trials, standing by can come
with important risks, including the same ones on which
the success of the research hinges. It is thus important
to consider the ethical obligations to protect bystan-
ders, and the related procedural responsibilities.
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